We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Intuitive Surgical's da Vinci and Ion systems anchor its growing minimally invasive care portfolio.
ISRG supports its ecosystem with digital tools, analytics, and surgeon training to boost procedural outcomes.
ISRG's ecosystem includes EndoWrist, SureForm staplers, and Firefly imaging to enhance surgical precision.
Intuitive Surgical (ISRG - Free Report) has built a comprehensive and integrated portfolio focused on advancing minimally invasive care, with its cornerstone being the da Vinci robotic surgical systems. The da Vinci platforms — ranging from the established multi-port Xi and X systems to the next-generation da Vinci 5 — enable surgeons to perform complex procedures through small incisions with enhanced precision, visualization and control. These systems are widely adopted across specialties such as urology, gynecology, general surgery, and thoracic care. Complementing the multi-port systems is the da Vinci SP (single-port) platform, designed for narrow-access procedures through a single incision, further minimizing patient trauma and recovery time.
Expanding beyond surgery, Intuitive’s Ion endoluminal system targets early-stage lung cancer diagnosis through minimally invasive robotic bronchoscopy. Ion is gaining strong commercial traction, diversifying ISRG’s revenues and broadening its presence in the diagnostic space. The portfolio also includes advanced surgical tools like EndoWrist instruments, SureForm staplers, SynchroSeal vessel sealers, and Firefly fluorescence imaging, all aimed at enhancing procedural efficiency and surgical outcomes.
Supporting this hardware ecosystem is a growing suite of digital and training tools, including the My Intuitive app, SimNow virtual simulators, and real-time analytics via Intuitive Hub. These offerings help improve surgeon proficiency and optimize workflow within hospitals. With over 12 million da Vinci procedures performed globally and more than 10,000 systems installed, Intuitive Surgical continues to solidify its position as a leader in minimally invasive care, leveraging technology to reduce open surgeries, improve outcomes and expand access worldwide.
Other Players in Minimal Invasive Space
Johnson & Johnson (JNJ - Free Report) , or J&J continues to invest heavily in its minimally invasive surgery portfolio through its MedTech division, particularly Ethicon. J&J’s offerings span advanced energy devices, surgical staplers, and robotic-assisted systems like the VELYS Robotic-Assisted Solution for orthopedic procedures. J&J is also developing the Ottava soft-tissue robotic system, aiming to challenge incumbents in the robotic-assisted surgery space. JNJ’s strength lies in its scale, legacy in surgical innovation, and integration across devices and digital platforms to support better surgical outcomes. With Ottava in clinical trials, J&J is positioning itself to gain share in the rapidly growing minimally invasive surgery market.
Edwards Lifesciences (EW - Free Report) is a leader in structural heart therapies, transforming minimally invasive care with its transcatheter aortic valve replacement (TAVR) solutions. EW’s SAPIEN valve platform is widely adopted, and the company continues to expand into mitral and tricuspid segments. With a strong pipeline and global reach, EW remains pivotal to minimally invasive surgery innovation.
ISRG’s Price Performance, Valuation and Estimates
Shares of ISRG have lost 1.9% in the year-to-date period compared with the industry’s decline of 11%.
Image Source: Zacks Investment Research
From a valuation standpoint, Intuitive Surgical trades at a forward price-to-sales ratio of 18.02, above the industry average. ISRG carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Intuitive Surgical’s 2025 earnings implies a 6.8% rise year over year.
Image: Shutterstock
ISRG's Minimally Invasive Ecosystem Powers Surgical Precision
Key Takeaways
Intuitive Surgical (ISRG - Free Report) has built a comprehensive and integrated portfolio focused on advancing minimally invasive care, with its cornerstone being the da Vinci robotic surgical systems. The da Vinci platforms — ranging from the established multi-port Xi and X systems to the next-generation da Vinci 5 — enable surgeons to perform complex procedures through small incisions with enhanced precision, visualization and control. These systems are widely adopted across specialties such as urology, gynecology, general surgery, and thoracic care. Complementing the multi-port systems is the da Vinci SP (single-port) platform, designed for narrow-access procedures through a single incision, further minimizing patient trauma and recovery time.
Expanding beyond surgery, Intuitive’s Ion endoluminal system targets early-stage lung cancer diagnosis through minimally invasive robotic bronchoscopy. Ion is gaining strong commercial traction, diversifying ISRG’s revenues and broadening its presence in the diagnostic space. The portfolio also includes advanced surgical tools like EndoWrist instruments, SureForm staplers, SynchroSeal vessel sealers, and Firefly fluorescence imaging, all aimed at enhancing procedural efficiency and surgical outcomes.
Supporting this hardware ecosystem is a growing suite of digital and training tools, including the My Intuitive app, SimNow virtual simulators, and real-time analytics via Intuitive Hub. These offerings help improve surgeon proficiency and optimize workflow within hospitals. With over 12 million da Vinci procedures performed globally and more than 10,000 systems installed, Intuitive Surgical continues to solidify its position as a leader in minimally invasive care, leveraging technology to reduce open surgeries, improve outcomes and expand access worldwide.
Other Players in Minimal Invasive Space
Johnson & Johnson (JNJ - Free Report) , or J&J continues to invest heavily in its minimally invasive surgery portfolio through its MedTech division, particularly Ethicon. J&J’s offerings span advanced energy devices, surgical staplers, and robotic-assisted systems like the VELYS Robotic-Assisted Solution for orthopedic procedures. J&J is also developing the Ottava soft-tissue robotic system, aiming to challenge incumbents in the robotic-assisted surgery space. JNJ’s strength lies in its scale, legacy in surgical innovation, and integration across devices and digital platforms to support better surgical outcomes. With Ottava in clinical trials, J&J is positioning itself to gain share in the rapidly growing minimally invasive surgery market.
Edwards Lifesciences (EW - Free Report) is a leader in structural heart therapies, transforming minimally invasive care with its transcatheter aortic valve replacement (TAVR) solutions. EW’s SAPIEN valve platform is widely adopted, and the company continues to expand into mitral and tricuspid segments. With a strong pipeline and global reach, EW remains pivotal to minimally invasive surgery innovation.
ISRG’s Price Performance, Valuation and Estimates
Shares of ISRG have lost 1.9% in the year-to-date period compared with the industry’s decline of 11%.
Image Source: Zacks Investment Research
From a valuation standpoint, Intuitive Surgical trades at a forward price-to-sales ratio of 18.02, above the industry average. ISRG carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Intuitive Surgical’s 2025 earnings implies a 6.8% rise year over year.
Image Source: Zacks Investment Research
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.